An investigation into the anxiety- and stress-relieving effects of Echinacea angustifolia (EP107™): a randomised, double-blind, placebo-controlled study

Clinical Research Australia0 个研究点目标入组 108 人开始时间: 2020年2月21日最近更新: 2021年2月16日

适应症

试验速览

暂无简介。

•1. Healthy adults (male and female) between 18 and 65
•2. Experiencing mild-to-moderate severity of stress/anxiety (score between 11 and 40 on the CUXOS)
•3. Stressor/anxiety has been present for greater than a month
•4. Medication-free for at least 3 months. Use of analgesics (once a week) or contraceptive pill are permissible.
•5. Non-smoker
•6. BMI between 20 and 35
•7. No plan to commence new treatments over study period
•8. Willing to provide a personally signed informed consent form detailing all pertinent aspects of the trial.
•9. Willing and able to take prescribed tablets for 6 weeks

•1. Alcohol consumption > 14 standard drinks per week
•2. Current or 12-month history of illicit drug abuse
•3. Pregnant women, women who are breastfeeding or women who intended to fall pregnant.
•4. Suffering from medical conditions including but not limited to: gastrointestinal disease, functional gastrointestinal disorder, diabetes, hyper/hypotension, cardiovascular disease, gallbladder disease/gallstones/biliary disease, endocrine disease, psychiatric disorder (other than mild-to-moderate anxiety), and neurological disease (Parkinson’s, Alzheimer’s disease, intracranial haemorrhage, head or brain injury)
•5. Currently taking supplements that may impact on treatment outcome

发起方

Clinical Research Australia